SUPRIYA — Supriya Lifescience Cashflow Statement
0.000.00%
- IN₹31.10bn
- IN₹30.36bn
- IN₹5.70bn
- 78
- 18
- 93
- 73
Annual cashflow statement for Supriya Lifescience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 962 | 1,673 | 2,072 | 1,235 | 1,657 |
Depreciation | |||||
Non-Cash Items | 38.6 | -9.22 | -29.1 | -46.1 | -134 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 96 | -973 | -1,657 | -645 | -548 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1,161 | 759 | 488 | 662 | 1,133 |
Capital Expenditures | -245 | -482 | -599 | -1,084 | -1,457 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | 14.4 | 0.82 | -247 | -279 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -245 | -468 | -598 | -1,331 | -1,736 |
Financing Cash Flow Items | -39.6 | 11.1 | 34.1 | 64.1 | -5.51 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -292 | -145 | 1,497 | -33.7 | -224 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 623 | 146 | 1,386 | -703 | -826 |